Perception and Prevalence of Fungal Infections in Berlin - Brandenburg
IFI_ICU
Web-based Structured Survey of Retrospective Data of Invasive Mycosis in Intensive Care Patients in Berlin - Brandenburg
1 other identifier
observational
25
1 country
1
Brief Summary
This is a structured web-based survey in selected hospitals with intensive care units in Berlin- Brandenburg that will focus on the analysis of current knowledge in ICUs in the field of invasive mycoses.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2011
CompletedFirst Submitted
Initial submission to the registry
July 5, 2011
CompletedFirst Posted
Study publicly available on registry
July 13, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2013
CompletedOctober 18, 2013
October 1, 2013
1 year
July 5, 2011
October 17, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Perception and prevalence of fungal infections
Perception and prevalence of fungal infections in ICU patients differs from real prevalence and leads to insufficient attribution of importance to this special medical condition.
4 months
Secondary Outcomes (1)
Practice - Surrogate markers for diagnosis and therapy of fungal infection and retrospective analysis of cases of invasive mycosis in a peer-review setting.
6 months
Study Arms (1)
INABBRA
Participating hospitals in the INABBRA alliance.
Eligibility Criteria
Intensive care units of different primary and secondary care hospitals in the region of Berlin-Brandenburg.
You may qualify if:
- Intensive care units of hospitals in the INABBRA alliance.
- Patients with invasive mycosis.
You may not qualify if:
- Hospitals without intensive care unit.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitaetsmedizin Berlin
Berlin, State of Berlin, 13353, Germany
Related Publications (1)
Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5. doi: 10.1128/AAC.49.9.3640-3645.2005.
PMID: 16127033BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Claudia Spies, Prof., MD
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitaetsmedizin Berlin
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charite University, Berlin
Study Record Dates
First Submitted
July 5, 2011
First Posted
July 13, 2011
Study Start
July 1, 2011
Primary Completion
July 1, 2012
Study Completion
July 1, 2013
Last Updated
October 18, 2013
Record last verified: 2013-10